THE IMPACT OF FAMILIAL HYPERCHOLESTEROLEMIA ON CARDIOVASCULAR DISEASE

  • Alexandra MASTALERU “Grigore T. Popa” University of Medicine and Pharmacy Iasi
  • Maria-Magdalena LEON-CONSTANTIN “Grigore T. Popa” University of Medicine and Pharmacy Iasi
  • Andra OANCEA “Grigore T. Popa” University of Medicine and Pharmacy Iasi
  • R.C. ANGHEL “Grigore T. Popa” University of Medicine and Pharmacy Iasi
  • Alexandra JITARU “Grigore T. Popa” University of Medicine and Pharmacy Iasi
  • F. MITU “Grigore T. Popa” University of Medicine and Pharmacy Iasi

Abstract

Familial hypercholesterolemia is one of the most common inherited diseases, that leads to an important cardiovascular morbidity and mortality, especially in developed countries. It is characterized by early coronary artery disease associated with cholesterol deposits that lead in time to atherosclerotic plaques, because of high levels of circulating cholesterol for a long period of time. Romania is in the group of countries at high risk for cardiovascular disease, being recommended that all internal medicine doctors and cardiologists use the SCORE Risk Chart, to calculate the cardiovascular risk for the next 10 years. The causes of hypercholesterolemia are multiple. On the one hand, the exogenous intake of dietary principles with high cholesterol content is incriminated, and on the other hand is the involvement of the genetic factor. Regarding the treatment in familial hypercholesterolemia, the most recent guidelines state that statins are the mainstay of treatment, but in addition we can also use new drugs like PCSK9 inhibitors, in combination with lifestyle changes. Through this article, we want to draw attention once again to the need for hypercholesterolemia treatment, in line with the latest recommendations of the guidelines.

Author Biographies

Alexandra MASTALERU, “Grigore T. Popa” University of Medicine and Pharmacy Iasi

Faculty of Medicine
Department of Medical Specialties (I)

Maria-Magdalena LEON-CONSTANTIN, “Grigore T. Popa” University of Medicine and Pharmacy Iasi

Faculty of Medicine
Department of Medical Specialties (I)

Andra OANCEA, “Grigore T. Popa” University of Medicine and Pharmacy Iasi

Faculty of Medicine
Department of Medical Specialties (I)

R.C. ANGHEL, “Grigore T. Popa” University of Medicine and Pharmacy Iasi

Faculty of Medicine
Department of Medical Specialties (I)

Alexandra JITARU, “Grigore T. Popa” University of Medicine and Pharmacy Iasi

Faculty of Medicine
Department of Medical Specialties (I)

F. MITU, “Grigore T. Popa” University of Medicine and Pharmacy Iasi

Faculty of Medicine
Department of Medical Specialties (I)

References

1. Kayikcioglu M, Tokgozoglu L, Dogan V, Ceyhan C, Tuncez A, Kutlu M et al. What have we learned from Turkish familial hypercholesterolemia registries (A-HIT1 and A-HIT2)? Atheroscl 2018; 277: 341-346.
2. Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, Drexel H et al. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias: The Task Force for the Management of Dyslipi-daemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) Developed with the special contribution of the European Assocciation for Cardiovascular Prevention & Rehabilitation (EACPR). Atheroscl 2016; 253: 281-344.
3. Gierach M, Gierach J, Junik R. Evaluation of lipid profiles in patients with metabolic syndrome ac-cording to cardiovascular risk calculated on the basis of the SCORE chart. Endokrynol Pol 2016; 67(3): 265-270.
4. Benn M, Watts GF, Tybjaerg-Hansen A, Nordestgaard BG.Familial hypercholesterolemia in the danish general population: prevalence, coronary artery disease, and cholesterol-lowering medication.J Clin Endocrinol Metab. 2012; 97(11): 3956-3964.
5. Nordestgaard BG, Chapman MJ, Humphries SE, Ginsberg HN, Masana L, Descamps OS et al. Famil-ial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis So-ciety.Eur Heart J 2013; 34(45): 3478-3490.
6. Knowles JW, Rader DJ, Khoury MJ. Cascade Screening for Familial Hypercholesterolemia and the Use of Genetic Testing.JAMA. 2017; 318(4): 381-382.
7. Ibarretxe D, Rodríguez-Borjabad C, Feliu A, Bilbao JÁ, Masana L, Plana N. Detecting familial hy-percholesterolemia earlier in life by actively searching for affected children: The DECOPIN project. Atheroscl 2018; 278: 210-216.
8. A. Saltijeral, L. Pérez de Isla, R. Alonso, O. Muñiz, J.L. Díaz-Díaz, F. Fuentes, et al., SAFEHEART Investigators, Attainment of LDL Cholesterol Treatment Goals in Children and Adolescents with Fa-milial Hypercholesterolemia. The SAFEHEART Follow-up Registry, Rev Española Cardiol 2017; 70: 444-450.
9. Ruel I, Brisson D, Aljenedil S, Awan Z, Baass A, Bélanger A et al. Simplified Canadian Definition for Familial Hypercholesterolemia.Can J Cardiol 2018; 34(9): 1210-1214.
10. Cracana IM, Stefaniu R, Mocanu V, et al. New developments in the approach and diagnosis of sarco-penia. Rev Med Chir Soc Med Nat 2016; 120(3): 491-496.
11. Singh S, Bittner V. Familial hypercholesterolemia-epidemiology, diagnosis, and screening. CurrAth-eroscler Rep 2015; 17(2): 482-489.
12. Al-Rasadi K, Al-Waili K, Al-Sabti HA, Al-Hinai A, Al-Hashmi K, Al-Zakwani I, et al. Criteria for Diagnosis of Familial Hypercholesterolemia: A Comprehensive Analysis of the Different Guidelines, Appraising their Suitability in the Omani Arab Population. Oman Med J 2014; 29(2): 85-91.
13. Agabiti Rosei E, Salvetti M. Management of Hypercholesterolemia, Appropriateness of Therapeutic Approaches and New Drugs in Patients with High Cardiovascular Risk. High Blood Press Cardiovasc Prev 2016; 23(3): 217-230.
14. Sanin V, Pfetsch V, Koenig W. Dyslipidemias and Cardiovascular Prevention: Tailoring Treatment According to Lipid Phenotype. Curr Cardiol Rep 2017; 19(7): 61-65.
15. Polychronopoulos G, Tziomalos K. Novel treatment options for the management of heterozygous familial hypercholesterolemia. Expert Rev Clin Pharmacol 2017; 10(12): 1375-1381.
Published
2018-12-27
Section
INTERNAL MEDICINE - PEDIATRICS